Online inquiry

IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4709MR)

This product GTTS-WQ4709MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4709MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7239MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ13177MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ8625MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ3516MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BART
GTTS-WQ9912MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ3044MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ35MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 2857916
GTTS-WQ3662MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1213790
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW